Time to test CLL p53 function

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia

(2010) D. Asslaber et al.   BLOOD

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

(2009) J. Malcikova et al.   BLOOD

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

(2009) T. Zenz et al.   BLOOD

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

(2009) M Mraz et al.   LEUKEMIA

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

(2008) I. Seyfried et al.   BLOOD

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

(2008) T. Zenz et al.   BLOOD

miR-34a as part of the resistance network in chronic lymphocytic leukemia

(2008) T. Zenz et al.   BLOOD

MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia

(2008) Irina Gryshchenko et al.   JOURNAL OF CLINICAL ONCOLOGY

17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation

(2008) M K Dijkstra et al.   LEUKEMIA